What is it? Why is it important?

The Risk Evaluation Matrix (REM) is a tool to visualize and assess risks by mapping a:

  • x-axis: Probability or likelihood of risk occurrence, considering contributing factors and detectability
  • y-axis: Expected impact on the study`s defined Critical to Quality (CtoQ) factors

 

Based on these dimensions, risks are scored typically on a scale reflecting both probability and impact (e.g. 1=low, 2=medium, 3=high). Scores interpretation should retain some flexibility considering study complexity and participant-centric risks.

 

Risks appearing in the top-right corner are high-priority risks with high likelihood and impact. These risks require the implementation of robust risk control-measures, including ongoing dynamic management strategies.

 

When assessing study risks, researchers should apply a “Quality-by-Design” (QbyD) approach to the study. The aim is to manage risks before they occur, thereby providing credible and useful study results.

What do I need to do?

As a SP-INV or Site-INV:

  • Familiarise yourself with the REM diagram and how to manage risks based on their location in the REM
  • Prioritise risks in the top-right REM corner, as they represent threats with high probability and severe impact on the study`s CtoQ factors (e.g. participant right and safety, data quality).

 

For high priority risks:

  • Engage a multidisciplinary team that can support you in defining applicable risk control-measures (e.g. study monitoring, risk management strategies with the inclusion of efficacy assessments).
  • Recognize that risk evaluation amd prioritization is a dynamic process. Study risks threatening CtoQ factors should be regularly reassessed, with risk control-measures updated to reflect new information on risk behaviour, changes in study conduct, or emerging technologies (e.g., digital tools, decentralized trial methods).
  • Apply proportionate and fit for purpose risk control-measures aimed at preventing and/or mitigating risk occurrence

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines

Documents

Abbreviations
  • CtoQ - critical-to-quality factors
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ICH - International Council for Harmonisation
  • ISO – International Organization for Standardization
  • QbyD – Quality by Design
  • REM – Risk Evaluation Matrix
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Evaluation Matrix
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Evaluation Matrix